Stage 4 HER2 Positive Breast Cancer: 54 Real Stories

54 stories match breast cancer, stage 4 and HER2 positive. 50 of them mention chemotherapy.

A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Hormone receptor-positive, HER2-positive breast cancer with later lung metastasis

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Metastatic Site: Lung

The patient had hormone receptor-positive, HER2-positive breast cancer treated with standard therapy, then developed lung metastasis years later and continued molecular targeted therapy indefinitely while asymptomatic from the metastasis.

AZ Oncology Japan
OutcomeLiving With Cancer
Regina, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Regina's Patient Story

Patient Info: Regina Ritter, Female, 50s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Liver | Lung

At the 2013 interview, Regina was living with metastatic HER2-positive breast cancer after liver metastasis at diagnosis, later recurrence, and inoperable lung metastasis treated with oral chemotherapy.

Krankheitserfahrungen.de
OutcomeLiving With Cancer
Leftfootforward, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Leftfootforward's Survivor Story

Patient Info: Leftfootforward, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain | Liver

Leftfootforward was diagnosed with Stage IIB HER2-positive breast cancer in 2010 and metastatic brain/liver disease in 2012; after systemic therapy, Gamma Knife, craniotomy for necrotic tissue, partial liver lobectomy, and resumed Herceptin, her latest scans showed no evidence of disease.

BreastCancer.org (ES)
OutcomeCancer-Free / NED
Pilar, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

MatchTrial Historias Reales
OutcomeLiving With Cancer
Leanne, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Lobular Carcinoma: Leanne's Patient Story

Patient Info: Leanne, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Brain

Leanne was first diagnosed in 2015 with Stage III triple-positive ILC and then diagnosed with metastatic lobular breast cancer with brain metastasis on April 4, 2018, causing major neurologic and work limitations.

Lobular Breast Cancer Alliance
OutcomeSetback / Progression
Jennifer, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-Farber
OutcomeLiving With Cancer
Tiffany, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Tiffany's Patient Story

Patient Info: Tiffany Andrews, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; ER-negative at recurrence

Metastatic Site: lungs|brain

Tiffany is living with metastatic HER2-positive breast cancer and continues treatment through a clinical trial after progression in the lungs and brain.

MD Anderson
OutcomeCare Ongoing
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Shari, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy
Renee, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic HER2-positive breast cancer complicated by severe low magnesium

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: bone|lungs|liver|brain

She died during a hospitalization for advanced metastatic breast cancer and severe treatment-related hypomagnesemia, with her final care focused on comfort.

PubMed Central
OutcomeIn Memory
Christina, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Christina's Patient Story

Patient Info: Christina, Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Liver; lymph nodes

Christina was living with Stage IV HER2-positive metastatic breast cancer. Treatment had cleared the liver disease and removed the visible breast tumor, but small armpit lymph-node disease required radiation and she continued IV treatment every 3 weeks.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER-positive/HER2-positive breast cancer with rare paranasal sinus and skull metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and paranasal sinus metastasis were ER positive, PR negative, HER2 positive; GATA3 supported breast origin in metastasis.

Metastatic Site: left frontal sinus; ethmoid air cells; posterior…

The paranasal sinus/skull metastasis did not respond to palliative radiotherapy; her condition deteriorated and she died 2 years after her initial presentation to the treating facility.

PubMed Central
OutcomeIn Memory
Sonja, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Sonja's Patient Story

Patient Info: Sonja Rideout, Female | Stage IV

Biomarkers: HER2-positive; Tempus testing later indicated immunotherapy as an option

Metastatic Site: Lungs; liver; bone: tailbone; thoracic lymph nodes

As of January 2026, Sonja was living with metastatic HER2-positive breast cancer after spread to lungs and liver, later tailbone and thoracic lymph nodes, and had moved to weekly carboplatin/gemcitabine plus monthly immunotherapy.

Susan G. Komen
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Synchronous EGFR-mutated lung adenocarcinoma and metastatic breast cancer: surgery and adjuvant therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Two cancers: lung adenocarcinoma with EGFR exon 19 deletion; breast cancer ER-positive, PR-low, HER2 non-amplified.

Metastatic Site: lung

Follow-up CT on 26 December 2024 showed no recurrence, with disease-free survival estimated at 27 months to 1 April 2025 while on icotinib and letrozole maintenance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed Central
OutcomeIn Memory
Paul, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of Hope
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed Central
OutcomeResponding Well
Elissa, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Elissa's Patient Story

Patient Info: Elissa, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; no hereditary mutation reported

Metastatic Site: lymph nodes, liver, spine

Elissa had Stage IV HER2-positive metastatic breast cancer with an early strong response to systemic therapy, but she described the disease as long-term and not curative. As of July 2025, she had lived with metastatic breast cancer for about 4 years and had received roughly 5 lines of treatment.

The Patient Story
OutcomeLiving With Cancer
Kathleen, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-Farber
OutcomeCare Ongoing
Jennifer, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Masters, Female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest wall/skin near surgery incision; lymph nodes

As of May 2025, Jennifer had no reported recurrence for several years after Stage IV HER2-positive metastatic breast cancer responded completely to clinical-trial treatment with T-DM1 and neratinib; she continued annual Cleveland Clinic visits and remained active with family and volunteering.

Cleveland Clinic
OutcomeCancer-Free / NED
Samantha, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy